About
Overview
Leadership
Area of Focus
Congestion in Heart Failure
Outpatient Parenteral Antimicrobial Treatment (OPAT)
Research and Development
FUROSCIX
®
(furosemide injection) for subcutaneous administration
scCeftriaxone
Clinical Development & Medical Affairs
Investor Relations
Investor Overview
Stock Information
Stock Quote & Chart
Historical Price Lookup
Investment Calculator
Corporate Governance
Governance Highlights
Committee Composition
Financial Information
Sec Filings
News & Events
News Releases
Event Calendar
Presentations
Investor Resources
Investor FAQ
Information Request
E-mail Alerts
Ir Contacts
Media Resources
Careers
Contact Us
Legal
Privacy Policy
Terms of Use
scPharmaceuticals
Areas of Focus
Research & Development
Careers
Recent News
December 07, 2020
scPharmaceuticals Inc. Receives Complete Response Letter from FDA for FUROSCIX
®
Read More
November 19, 2020
scPharmaceuticals to Present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference
Read More
November 16, 2020
scPharmaceuticals Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update
Read More
November 11, 2020
scPharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Read More
All News